XML 16 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Cash Flows from Operating Activities    
Net income $ 2,558,654 $ 2,810,476
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 292,318 278,637
Amortization of debt issuance cost 44,041 66,039
Loss on sale of assets 2,877
Stock based compensation expense 339,136 302,641
Change in the fair value of derivative liability (1,086,498)
Remeasurement loss (gain) on translation of foreign subsidiary 14,243 (240,806)
Foreign currency transaction loss 76,849
Non cash implied interest 23,194 42,717
Amortization of debt discount 475,600
Changes in operating assets and liabilities:    
Accounts receivable (1,031,743) 2,361,207
Inventory 362,153 9,815
Prepaid expense 16,119 (80,433)
Accounts payable and accrued liabilities (994,245) (1,514,226)
Deferred revenue (27,267)
Net cash provided by operating activities 1,676,330 3,425,171
Cash Flows from Investing Activities    
Payments for acquisition of fixed assets (53,594) (62,921)
Proceeds from sale of assets 6,199
Restricted cash (38,188) 448,942
Net cash (used in) provided by investing activities (85,583) 386,021
Cash Flows from Financing Activities    
Repayment of notes payable (2,387,500) (1,137,500)
Payment of earn out liability (2,551,500)
Net cash used in financing activities (2,387,500) (3,689,000)
Effect of exchange rate on cash and cash equivalents (5,901)
Net (decrease) increase in cash and cash equivalents (802,654) 122,192
Cash and Cash Equivalents, beginning of period 2,517,642 3,640,893
Cash and Cash Equivalents, end of period 1,714,988 3,763,085
Supplemental Disclosure of Cash Flow Information:    
Interest 243,088 407,560
Income taxes 411,075 141,447
Supplemental Disclosure of Non-cash Investing and Financing Activities:    
Reallocation of goodwill related to acquisition of Factor Nutrition to intellectual property $ 450,000